Search Results - "MASS, M. K"

Eight-year follow-up study of brain atrophy in patients with MS by FISHER, E, RUDICK, R. A, SIMONIAN, N. A, SIMON, J. H, CUTTER, G, BAIER, M, LEE, J.-C, MILLER, D, WEINSTOCK-GUTTMAN, B, MASS, M. K, DOUGHERTY, D. S

“…To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if…”
Get full text

Use of the multiple sclerosis Functional Composite to predict disability in relapsing MS by RUDICK, R. A, CUTTER, G, BAIER, M, FISHER, E, DOUGHERTY, D, WEINSTOCK-GUTTMAN, B, MASS, M. K, MILLER, D, SIMONIAN, N. A

“…To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS). The MSFC was…”
Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients by Rudick, R A, Cutter, G R, Baier, M, Weinstock-Guttman, B, Mass, M K, Fisher, E, Miller, D M, Sandrock, A W

“…Two methods were used to estimate the long-term impact of disease-modifying drug therapy (DMDT) in patients with relapsing multiple sclerosis (MS) who…”
Get full text

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients by Fisher, E., Rudick, R.A., Cutter, G., Baier, M., Miller, D., Weinstock-Guttman, B., Mass, M.K., Dougherty, D.S., Simonian, N.A.

“…Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: Multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis by Nance, P W, Sheremata, W A, Lynch, S G, Vollmer, T, Hudson, S, Francis, G S, O'Connor, P, Cohen, J A, Schapiro, R T, Whitham, R, Mass, M K, Lindsey, J W, Shellenberger, K

“…Spasticity is a serious problem in multiple sclerosis (MS) and many patients do not achieve a satisfactory response to currently available oral antispasticity…”
Get more information

Myelination of axons within cytosine arabinoside treated mouse cerebellar explants by cultured rat oligodendrocytes by Seil, F J, Johnson, M L, Saneto, R P, Herndon, R M, Mass, M K

“…Cell suspensions of cultured purified rat oligodendrocytes prepared by the differential substrate adhesion method were applied to neonatal mouse cerebellar…”
Get more information

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients by Fisher, E, Rudick, R A, Cutter, G, Baier, M, Miller, D, Weinstock-Guttman, B, Mass, M K, Dougherty, D S, Simonian, N A

“…Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential…”
Get full text

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex registered treatment in patients with multiple sclerosis by Herndon, R M, Rudick, R A, Munschauer, FE III, Mass, M K, Salazar, A M, Coats, ME, Labutta, R, Richert, J R, Cohan, S L, Genain, C, Goodkin, D, Toal, M, Riester, K

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFN beta -1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Factors that predict health-related Quality of Life in patients with relapsing-remitting multiple sclerosis by MILLER, Deborah M, RUDICK, Richard A, BAIER, Monika, CUTTER, Gary, DOUGHTERY, David S, WEINSTOCK-GUTTMAN, Bianca, MASS, Michele K, FISHER, Elizabeth, SIMONIAN, Nancy

“…Health-Related Quality of Life (HRQoL) research is gaining acceptance in the field of multiple sclerosis (MS). Little is known about what precipitates quality…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997 by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Pullicino, P M, Scherokman, B J, Weistock-Guttman, B, Whitham, R H

Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Simonian, N A, Alam, J A, Campion, M, Scaramucci, J O, Jones, W, Coats, M E, Goodkin, D E, Weinstock-Guttman, B, Herndon, R M, Mass, M K, Richert, J R, Salazar, A M, Munschauer, 3rd, F E, Cookfair, D L, Simon, J H, Jacobs, L D

“…Interferon beta is an effective treatment for relapsing multiple sclerosis (MS). As with other protein drugs, neutralizing antibodies (NAB) can develop that…”
Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group by Rudick, R A, Cookfair, D L, Simonian, N A, Ransohoff, R M, Richert, J R, Jacobs, L D, Herndon, R M, Salazar, A M, Fischer, J S, Granger, C V, Goodkin, D E, Simon, J H, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munchsauer, F E, O'Reilly, K, Priore, R L, Whitham, R H

“…This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III…”
Get full text

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Goodkin, D E, Priore, R L, Wende, K E, Campion, M, Bourdette, D N, Herndon, R M, Fischer, J S, Jacobs, L D, Cookfair, D L, Rudick, R A, Richert, J R, Salazar, A M, Granger, C V, Simon, J H, Alam, J J, Bartoszak, D M, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, 3rd, F E, Whitham, R H

“…We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25…”
Get more information

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Whitham, R H

“…A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed…”
Get full text